argenx SE
XBRU:ARGX
argenx SE
XBRU:ARGX
Price:
339.9 EUR
-1.45%
Market Closed
Updated:
May 19, 2024
argenx SE
Income from Continuing Operations
|
argenx SE
Income from Continuing Operations Peer Comparison
Comparables:
PHARM
PRQR
QURE
MRUS
N
NAMS
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
argenx SE
XBRU:ARGX
|
Income from Continuing Operations
-$429.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Income from Continuing Operations
-$10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Income from Continuing Operations
-€26.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Income from Continuing Operations
-$296.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-22%
|
|
|
Merus NV
NASDAQ:MRUS
|
Income from Continuing Operations
-$149.6m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Income from Continuing Operations
-€78.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is argenx SE's Income from Continuing Operations?
Income from Continuing Operations
-429.3m
USD
-429.3m
USD
Based on the financial report for Mar 31, 2024, argenx SE's Income from Continuing Operations amounts to -429.3m USD.
What is argenx SE's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-49%
-49%
Over the last year, the Income from Continuing Operations growth was 56%. The average annual Income from Continuing Operations growth rates for argenx SE have been 20% over the past three years , -49% over the past five years .
You don't have any saved screeners yet
